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Introduction 
Mid-infrared spectroscopic imaging is a rapidly emerging technique in biomedical research and 
clinical diagnostics that takes advantage of the unique molecular fingerprint of cells, tissue and 
biofluids to provide a rich biochemical image without the need for staining. Spectroscopic 
analysis allows for the objective classification of biological material at a molecular level [1]. This 
 ?ůĂďĞů ĨƌĞĞ ?molecular imaging technique has been applied to histology, cytology, surgical 
pathology, microbiology and stem cell research, and can be used to detect subtle changes to the 
genome, proteome and metabolome [2-4]. The new wealth of biochemical information made 
available by this technique has the distinct potential to improve cancer patient outcome through 
the identification of earlier stages of disease, drug resistance, new disease states, and high-risk 
populations [4]. However, despite the maturity of this science, instrumentation that provide 
increased sample throughput, improved image quality, a small footprint, low maintenance, and 
require minimal spectral expertise are essential for clinical translation. 
The latest generation of Fourier Transform infrared (FT-IR) spectrometers, that incorporate large 
liquid nitrogen cooled focal plane array (FPA) detectors within an infrared microscope system, 
have no doubt accelerated the development of the field. An FPA detector is a 2D device that is 
sensitive to the infrared region of the electromagnetic spectrum and consists of an array of 
photon-sensitive pixels on the focal-plane of a lens [5]. Significant improvements in data 
acquisition, processing, and classification times, in part due to the increased field of view (FOV) 
of these FPA based devices, have enabled spectroscopic investigations that now include clinically 
relevant patient populations [6]. Nevertheless, despite these marked improvements when 
compared to linear detector array (LDA) or point detector based systems, data collection times 
from tissue micro-array (TMA) cores or whole tissue sections are still in the order of hours or days 
[7]. The problem can be characterised in part by the tradeoff that must be made between spatial 
and spectral resolution, and the signal to noise ratio required to provide robust spectral 
classification.  Utilising a low magnification objective increases the FOV and signal to noise ratio 
of the recorded data, thereby allowing larger areas of the sample to be imaged more rapidly.  
However, smaller spatial features within the sample cannot be resolved, so consequently there 
is a need for high definition, diffraction-limited, spatial resolution for the identification and 
classification of early stages of disease. However, without the photon throughput available from 
a synchrotron source, and the requirement of high magnification reflective optics that offer a 
much reduced FOV, acquisition times can dramatically increase to acquire images of adequate 
size and signal to noise ratio.  Furthermore, the multiplex advantage exploited by traditional 
Fourier Transform based systems can be computationally prohibitive, requiring large amounts of 
readout data to be processed before subsequent reduction to only a few key wavelengths or 
spectral biomarkers used for classification.  This has led to a debate within the field as to whether 
all spectral frequencies need to be collected once a set of specific spectral biomarkers have been 
identified, and thus instead explore more efficient non-interferometric methods of data 
collection. 
 
Quantum Cascade Laser (QCL) based mid-infrared imaging 
Recently, broadly tunable mid-infrared quantum cascade lasers (QCLs) have been successfully 
integrated within a microscope for spectrochemical imaging across the molecular fingerprint 
region [8].  The main components of this type of microscope include multiple QCL modules, an 
optical multiplexer, a condenser, a switchable objective, an automated stage and an FPA detector 
system.  No longer requiring an interferometer, simpler instrument architecture can be achieved 
allowing a reduced footprint; approximately a third of high-end commercial FT-IR bench and 
microscope systems [8].  The high brightness of these broadly tunable QCL sources has also 
enabled the use of large format (480 x 480) uncooled microbolometer detector systems, 
removing the need for a cryogenically cooled mercury cadmium telluride (MCT) based detector 
system.  Of particular note has been the development of purpose designed high numerical 
aperture (NA), achromatic, wide-field and refractive based infrared objectives. The unique 
combination of a broadly tunable laser source, refractive based objectives optimized for coherent 
light, and a large format detector system, has enabled high-definition diffraction-limited 
resolution without a trade-off in signal-to-noise and field of view, as associated with FT-IR 
microscopes with their extended globar thermal light sources.  Utilising a tunable laser as a 
source also provides new modalities of data collection not previously available. Real-time 
discrete frequency spectrochemical imaging at 30 frames per second is a modality that can 
provide a number of unique applications, allowing the user to quickly screen large samples, 
moving back and forth between a handful of important frequencies that enhance chemical 
contrast of the sample and help segment areas of disease. This type of modality would suit intra-
operative tumor screening of frozen biopsy tissue or multiplexed chemotyping of cells or 
biofluids.  Another unique modality is the ability to perform a sparse frequency data collection, 
whereby a target set of discrete frequencies can be collected.  During the learning phase of a 
spectral diagnostic, it is clearly wise to acquire data from the full spectral range in order to mine 
the spectral patterns between class types.  However, once the learning phase is complete, and 
the most diagnostic spectral features have been identified, a targeted list of only a few key 
wavelengths needs to be collected by the instrument, thereby greatly improving acquisition time 
and sample throughput. 
 
High-resolution mid-infrared spectrochemical imaging of tissue 
The current method for diagnosis of cancer is histopathology. This method requires a trained 
pathologist, often a specialist (e.g. neuropathologist) to interpret morphometric changes in 
cellular and tissue architecture to render a diagnosis.  The technique has a long diagnostic 
window and can be prohibitively subjective [9]. Limitations with this diagnostic modality have led 
to an interest in the development of spectroscopic analytical techniques for the diagnosis of 
cancer [10]. 
All mid-infrared based microscope systems are inevitably limited by a trade-off between spatial 
resolution, signal-to noise ratio, field of view, and acquisition time. Traditionally with a 
conventional bench top FT-IR based system, to achieve true diffraction-limited resolution, high 
magnification objectives with the largest possible numerical aperture (NA) are required that 
provide a much reduced field of view and extended sample dwell times to achieve an acceptable 
signal-to-noise ratio for tissue classification purposes [11].  Previous rigorous analysis indicates 
ƚŚĂƚ ŝƚ ŝƐ ĂůƐŽ ŝŵƉĞƌĂƚŝǀĞ ƚŽ ƉƌŽǀŝĚĞ ĂŶ ĞĨĨĞĐƚŝǀĞ ƉŝǆĞů ƐƉĂĐŝŶŐ ŽĨ  ?ʄ ? ? ĂƐƐƵŵŝŶŐ ƚŚĞ ďĞƐƚ
commercially available NA of ~0.65. However, these calculations were based on models of a 
circular objective, whereas a classical Cassegrain objective is annular.  Nevertheless, when 
combining high magnification objectives on the order of 36x and above, with a 128 x 128 FPA 
detector system, the best FOV achievable is on the order of 150 µm x 150 µm with a pixel 
resolution of 1.1 µm.  Given these drawbacks the application of high resolution imaging for 
spectral tissue classification has been limited, with a preference to perform lower resolution 
imaging with a larger FOV in order to increase sample throughput.  More recently however, the 
application of high resolution imaging for clinical diagnostics has shown clear advantages for the 
identification of small tissue structures that are essential for detecting early forms of disease [12].  
Traditional histochemical and immunohistochemical staining, despite their drawbacks of inter-
observer variability of morphological interpretation, are still very reliable for gross tumor 
identification and subtyping, providing a difficult technology to disrupt with an infrared spectral 
diagnostic.  However, mid-infrared spectral imaging is more likely to make a real and beneficial 
impact in pathology by identifying earlier forms of disease that cannot be identified by these 
methods, and are described by very small changes in the biochemical components of glandular, 
endothelial and myoepithlial cells, or intra-lobular stroma.  Thus, a technology that can provide 
high fidelity spectral data at this scale is likely essential for clinical translation. 
The recent development of the Spero ? microscope (Daylight Solutions Inc., San Diego, CA, USA), 
a laser based mid-infrared microscope, provides the capability to perform diffraction-limited 
imaging across the molecular fingerprint region (900  W 1800 cm-1) but from a much enhanced 
FOV.  By use of the high magnification refractive based objective of this instrument, which has a 
NA of 0.7 and a magnification of 12.5x, a FOV of 650 µm x 650 µm can be achieved, with a sample-
referred pixel size of 1.36 µm.  This equates to a ~20x enhancement in the FOV, making high 
resolution imaging of samples a more viable option, and has been measured via a USAF (United 
States Air Force) military target to achieve diffraction limited resolution of 5µm at 1650 cm-1, 
corresponding to the peak of a typical Amide I band.   
Figure 1 shows spectral images of the 1650 cm-1 band intensity recorded across medullablastoma 
and glioblastoma (types of brain cancer) tissue core slices (approx. 1.5 mm in diameter, 5 µm 
thickness, placed on CaF2 substrate) imaged using the Spero QCL microscope (A, C and E) and an 
FT-IR based microscope with a 128 x 128 FPA detector system (B, D and F). Figures 1E and 1F 
show zoomed images of the areas highlighted by the white box in Figures 1C and 1D, respectively. 
Images were acquired by performing a 3 x 3 camera tile mosaic of each tissue core.  The QCL 
microscope system utilised a 12.5x magnification objective with a NA of 0.7 to provide a FOV of 
650 x 650 µm and a pixel size of 1.36 µm for each tile. Data was acquired from 900  W 1800 cm-1 
with a spectral resolution of 4 cm-1 and took 2.1 hrs. The FT-IR microscope utilized a 15x 
magnification objective with a NA of ~0.65 to provide a FOV of 700 x 700 µm and a pixel size of 
5.5 µm for each tile.  Data was acquired from 950  W 3800 cm-1 with a spectral resolution of 4 cm-
1, 1x zero filling factor, Blackman Harris apodisation, and took 2.25 hrs.  All spectroscopic data 
was acquired in transmission geometry.   
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Figure 1 Spectral images of the 1650 cm-1 band intensity across medullablastoma (A and B) and 
glioblastoma (C, D, E and F) tissue cores (approx. 1.5 mm diameter and 5 µm thickness) imaged 
using a Spero QCL microscope (A, C and E) and a 128 x 128 FPA microscope system (B, D and F). 
1E and 1F are zoomed images of the areas highlighted by the white boxes on 1C and 1D of the 
glioblastoma tissue core. Spectra from the areas highlighted in red on C and D are shown for the 
QCL microscope (G) and for the FT-IR 128 x 128 system (H) 
 
The higher-resolution data acquired using the QCL microscope clearly provide images with 
superior clarity and allow fine tissue features to be visualized.  By enabling small but important 
tissue features to be resolved, spectrochemical information can be unlocked to not only identify 
early and rare forms of diseases, but also isolated primary and metastatic tumor cells, providing 
the potential to uncover previously unavailable information for the clinical sphere.  In addition, 
once a subset of diagnostic discriminatory frequencies has been identified (see biofluid section 
below), acquisition times can be markedly reduced since a QCL based system can, as mentioned 
above, be tuned to only acquire data from frequencies of interest, and therefore allow more 
clinically relevant timescales to be achieved.  This technology has a huge potential to help enable 
spectrochemical histopathology and drive forward the technique being applied in surgical 
pathology for highly important intra-operative decisions.   
Wide-field mid-infrared spectrochemical imaging of biofluids 
Biofluids (e.g. urine and serum) provide an easily accessible, relatively non-invasive sample for 
analysis the collection time for which can be performed worldwide and in the field [13]. The 
application of mid-infrared spectroscopy to characterise and classify human biofluids is a rapidly 
emerging field with a multitude of researchers now providing strong evidence that both primary 
and metastatic cancers and other auto-immune diseases can be identified and robustly classified 
[14]. The success is due in part by the application of a holistic approach, whereby the entire 
biochemical make up of the biofluids is scrutinized, rather than a small subset of biomarkers that 
can often result in misleading interpretations [13]. Research to date has been performed using a 
variety of different techniques, namely attenuated total reflection (ATR) and conventional 
imaging of dried biofluids spots [15,16,17].  However, a viable spectroscopic method for high 
throughput multiplexed screening of large patient populations is still lacking. One route toward 
this goal could be the rapid infrared imaging of biofluid spots that have been prepared in a patient 
orientated grid map.  For example, the x-dimension of such a grid could describe Ă ƉĂƚŝĞŶƚ ?Ɛ 
biofluid profile from different organs or extracted biochemical components therein, and the y-
ĚŝŵĞŶƐŝŽŶĚŝĨĨĞƌĞŶƚƉĂƚŝĞŶƚ ?Ɛ ?tŚĞŶƵƚŝůŝƐŝŶŐĂƐĞƐƐŝůĞĚƌŽƉƚĞĐŚŶŝƋƵĞ ?circular films on the order 
of 1  W 2 mm in diameter are formed when using 0.5 µl of fluid, the smallest reliable measurement 
using handheld pipettes. The dried spots can describe variable topology, but provide what is 
more commonly known as the coffee stain effect, whereby a thick ring is formed on the 
surrounding edges of the spot. Within this ring the data recorded is often compromised since the 
absorbance intensities measured for protein bands can often be outside the linear range of the 
detector response and show saturation. However, within the middle of the spot, a large area can 
be actively extracted for spectral analysis. What is also inherently different with dried biofluids, 
and somewhat advantageous over tissue or cell analysis, is the relatively homogenous sample 
morphology that in turn provides spectral data relatively free of adverse scattering.  Spectral 
profiles show little if any broad baseline oscillation allowing robust classification algorithms to be 
constructed without rigorous scattering correction.  
By use of the low magnification refractive based objective of the QCL microscope system, which 
has a NA of 0.15 and a magnification of 4x, a FOV of 2 mm x 2 mm can be achieved. This objective 
allows an entire dried biofluid spot to be examined in a single camera shot, with a sample-
referred pixel size of 4.25 µm and a spatial resolution on the order of 25 µm at 1650 cm-1. Given 
the homogenous nature of the sample deposition, spatial resolution is not an absolute necessity 
for this type of analysis, and the wide-field imaging capability allows for a more rapid assessment 
of the entire dried spot.  Since these types of samples do not provide adverse scattering profiles 
they are also an ideal candidate for a sparse frequency data collection protocol, whereby a 
reduced number of discrete wavelengths are targeted rather than collecting a more time 
prohibitive full spectrum. 
Figure 2 displays spectrochemical imaging analysis of a spotted human serum sample prepared 
onto a CaF2 substrate. Each serum spot was deposited manually using a micro-pipette and 0.5 µl 
of sample per patient, to form a grid of 2 x 5 spots.  The columns of the grid describe patients 
diagnosed as having a normal, brain, lung, breast, and skin cancer diagnoses, respectively. Each 
deposited serum spot was ca. 2 mm in diameter. The entire grid of serum spots was subsequently 
analysed using the wide-field 4x objective of the QCL microscope system using a discrete 
frequency collection protocol. Intensity values at 14 discrete wavenumbers (1000, 1030, 1080, 
1482, 1520, 1546, 1570, 1600, 1630, 1654, 1686, 1726, 1734, and 1770 cm-1), associated with the 
peak maxima and shoulders of absorption bands associated with lipid, protein, nucleic acid and 
carbohydrate macromolecules, were recorded from a total of 24 frames in a total time of 50 
minutes (ca. 2 minutes per tile); these absorption bands have previously been shown to be salient 
discriminating bands when comparing ATR/FT-IR recorded spectra from cancerous and non-
cancerous blood serum spots [16,17].  The image in figure 2A was constructed by plotting the 
recorded intensity value at 1654 cm-1 and allows the serum morphology to be easily visualized, 
often highlighting the coffee ring like shape of the serum deposits ? outer rims; spatial areas of 
the image mosaic highlighted as red correspond to high absorption of the 1654 cm-1 wavenumber 
frequency and spatial areas of the image mosaic highlighted as blue correspond to no absorption 
or very little absorption at the 1654 cm-1 wavenumber frequency. By use of a quality test that 
probes sample absorbance, a threshold criterion was utilised to extract pixels that were 
contained within the central part of the serum spots and did not describe saturation of the Amide 
I and Amide II protein specific bands.  The remainder of the multivariate data (chemometric) 
analysis was performed on 11 discrete frequencies (1482, 1520, 1546, 1570, 1600, 1630, 1654, 
1686, 1726, 1734, and 1770 cm-1), that predominantly describe protein and lipid profiles, in order 
to assess their ability to segment healthy from diseased patients.  Figure 2B displays all extracted 
spectra after baseline correction and vector normlisation.  Figure 2C conversely displays the 
average spectra calculated for the two normal (black) and two brain cancer (blue) serum spots. 
Even at this very basic mean spectrum level, spectral differences between these groups can be 
visualized. A more comprehensive chemometric analysis using all of the spectra extracted from 
the normal and brain cancer serum spots was performed using both principal component analysis 
(PCA), as shown in Figure 2D, and peak centroid analysis, as shown in Figure 2E. PCA analysis was 
performed using all 11 discrete frequencies of the data, whereas the peak centroid analysis was 
performed using the 9 frequencies associated with the Amide I and Amide II bands alone. Each 
dot in the figures represents a single pixel spectrum, whereby the black colour denotes a normal 
diagnosis (3242 spectra), and the blue color brain cancer (1899 spectra). 
 
Figure 2 (A) Mosaic image of serum spots acquired using 14 discrete frequencies from non-
cancer, brain cancer, lung cancer, breast cancer and skin cancer patients; (B) baseline corrected 
and vector normalized serum spectra extracted from the centre of the non-cancer and brain 
cancer serum spots; (C) mean spectra from each non-cancer (black) and brain cancer (blue) 
serum spot; (D) PCA scores plot of brain cancer serum spectra (blue) and non-cancer serum 
spectra (black), and (E) peak centroid distribution plot of the Amide I and Amide II bands for the 
brain cancer (blue) and non-cancer (black) serum spectra. 
 
These preliminary results (shown in Figure 2) clearly show that through recording a reduced 
number of wavelength frequencies the structural shape of the Amide I and II absorption bands 
can still be maintained. Thus, band shifts in frequency and band structural shape changes due to 
disease state can still be captured from the recorded data. Therefore, the results highlight the 
time advantage that can be made when adopting a sparse frequency collection paradigm for 
diagnostic applications, with no resulting penalty in the accuracy of data classification. Salient 
features for the differentiation of non-cancer and brain cancer serum spots can be easily 
extracted with PCA and then targeted by a sparse frequency data collection, achieving robust 
classification using the shift in peak centroid of the Amide I and Amide II bands alone. Previous 
investigations of the serum samples used in this study, whereby spectral data was collected using 
a traditional FT-IR based system from the entire mid-IR window (4000  W 400 cm-1), identified the 
very same peaks and features as being implicated in the discrimination of disease states [16, 17]. 
However, such data sets comprised intensity values from over 900 wavelength dimensions, the 
overwhelming majority of which are not important for classification purposes, and can 
necessitate computationally expensive Fourier transformation and pertinent wavelength 
extraction.  The use of a tunable laser based microscope has conversely allowed the focused 
acquisition of 14 pertinent mid-infrared spectral features required for classification, representing 
a step change in spectral image collection speed, within a clinically relevant time scale. Further 
studies are ongoing and include the utilisation of the nucleic acid and glycation associated 
discrete frequencies to segment multiple primary and metastatic cancers, but also the use of 
state of the art piezo-electric jetting devices for sample deposition. 
Conclusions 
The advent and application of QCL technology to the mid-infrared spectroscopic microscopic 
evaluation of biomedical samples is likely to rapidly expand over the next few years. The 
successful coupling of a tunable laser source with refractive based optics and large room 
temperature FPA cameras has opened a new door for practical spectral pathology.  As evidenced 
in this contribution, spectroscopic images with a fidelity and definition relevant to clinical needs 
are now viable, and multiplexed imaging analysis can be performed using discrete frequency 
targeting protocols.  
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